May 28: Drug maker Zydus Cadila on Monday announced that it has received the final approval from the USFDA to market Nystatin Ointment USP, 100,000 units per gram.
According to the company, the product is used as an adjunct to treat fungal skin infections and will be manufactured at the group’s topical manufacturing facility at Ahmedabad.
Meanwhile, the group also received the final approval to market its Omeprazole and Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg. It is used as to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs 367, down 4.05% from the previous closing of Rs 382.50, on BSE at 11.28 am today.